Print PDF

Sheppard Mullin Represents Signet Healthcare Partners in Investment in Goodwin Biotechnology


Sheppard Mullin represented Signet Healthcare Partners, a New York-based growth equity firm specializing in healthcare investments, in a significant growth capital investment in Goodwin Biotechnology, a leading contract manufacturer of monoclonal antibodies, recombinant proteins, vaccines, and Biologic Drug Conjugates including Antibody Drug Conjugates (ADCs) for early and late-stage clinical trials.  The investment will be used to help Goodwin double its space available for cGMP capacity as it readies for further expansion of its biopharmaceutical manufacturing.

The Sheppard Mullin team, led by partner Shon Glusky (NY), included special Counsel Farha Chowdry and Carol Archer; and attorney Nathaniel Schlakman.

Click here to read the Goodwin Biotechnology press release.

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.